Accessibility Menu
BrainsWay logo

BrainsWay(NASDAQ) BWAY

Market Cap$634.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+185%
5 Year+297%
1 Year+170%
1 Month+4%
$15.38
-2.66%
-0.42Today
BrainsWay last closing stock price
MetricPriceDate
Last closeUSD 15.802026-08-04
BrainsWay stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2%USD 15.492026-07-28
1 month+4.02%USD 15.192026-07-02
3 month-3.72%USD 16.412026-05-06
Year to date+66.14%USD 9.512025-12-31
1 year+169.62%USD 5.862025-08-04
3 year+1,233.33%USD 1.192023-08-04
5 year+297.48%USD 3.982021-08-05
Since inception+185.12%USD 5.552019-04-17

BrainsWay Financials at a Glance

Market Cap

$634.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$56.22M

Net Income (TTM)

$8.82M

EPS (TTM)

$0.22

P/E Ratio

69.57

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$15.38

Volume

13,257.995

Open

$15.77

Previous Close

$15.80

Daily Range

$15.04 - $15.77

52-Week Range

$5.81 - $17.35

Estimated Earnings Date

Aug 12, 2026

BWAY News

No articles available.

BWAY: Motley Fool Moneyball Superscore

79

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BrainsWay

BrainsWay Ltd. is a medical device company specializing in non-invasive neurostimulation treatments for mental health disorders. The company is at the forefront of this industry with its Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which targets deeper brain regions than traditional methods.

Products and Services

Deep Transcranial Magnetic Stimulation (Deep TMS) for mental health disorders

Specialized treatments for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD)

Research and development efforts for broader mental health applications

What Makes BrainsWay Ltd. Special

BrainsWay Ltd. distinguishes itself with its proprietary Deep TMS technology, which offers an innovative treatment alternative for patients unresponsive to standard therapies. This technology targets brain areas more effectively, providing a competitive edge in the treatment of depression and OCD.

Five Things You Need to Know

BrainsWay Ltd. focuses on advanced, non-invasive neurostimulation treatments for mental health disorders.

The company has developed a unique Deep TMS technology that sets it apart from traditional treatments.

Leadership in psychiatry and neurotechnology drives the company's research and development efforts.

Strategic collaborations with healthcare providers and research institutions enhance credibility and clinical adoption.

The company aims for geographic expansion and increased market penetration through strategic partnerships and regulatory approvals.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

129

CEO

Hadar Levy, CPA

Website

www.brainsway.com

Headquarters

Jerusalem, JM 9777518, IL

BWAY Financials

Key Financial Metrics (TTM)

Gross Margin

75.50%

Operating Margin

10.09%

Net Income Margin

14.57%

Return on Equity

12.28%

Return on Capital

5.40%

Return on Assets

7.54%

Earnings Yield

1.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$634.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.13M

Volume

13.26K

Avg. Volume

130.14K

Financials (TTM)

Gross Profit

$42.45M

Operating Income

$5.75M

EBITDA

$12.57M

Operating Cash Flow

$14.18M

Capital Expenditure

-$2.74M

Free Cash Flow

$11.45M

Cash & ST Invst.

$59.77M

Total Debt

$6.71M

BrainsWay Performance Analysis

BrainsWay annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 27,070,664-8.8%
20232023-12-31USD 31,703,09617.1%
20242024-12-31USD 41,210,67030.0%
20252025-12-31USD 52,639,30027.7%
BrainsWay sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-309.5%
Q32025-09-307.0%
Q42025-12-317.6%
Q12026-03-316.8%
BrainsWay annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.4094.2%
20232023-12-31USD -0.13-68.7%
20242024-12-31USD 0.06N/A
20252025-12-31USD 0.18230.4%
BrainsWay sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30150.0%
Q32025-09-30-20.0%
Q42025-12-31252.0%
Q12026-03-31-14.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.53M

+34.6%

Gross Profit

$11.68M

+35.6%

Gross Margin

75.17%

N/A

Market Cap

$634.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.92M

N/A

Employees

129

N/A

Net Income

$2.29M

+106.9%

EBITDA

$3.19M

+42.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$59.77M

-16.5%

Total Debt

$6.71M

+20.5%

Accounts Receivable

$7.53M

+8.3%

Inventory

$7.08M

+51.2%

Long Term Debt

$5.60M

+18.0%

Short Term Debt

$1.11M

+35.1%

Return on Assets

7.54%

N/A

Return on Invested Capital

6.54%

N/A

Free Cash Flow

$402.00K

-89.9%

Operating Cash Flow

$1.17M

-76.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCMDTactile Systems Technology, Inc.
$29.67-1.58%
NPCENeuroPace, Inc.
$14.00-0.99%
CERSCerus Corporation
$2.24+2.28%
DCTHDelcath Systems, Inc.
$12.90-1.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
YXTYxt.com Group
$7.02+1.70%
SPCXSpace Exploration Technologies
$113.40-0.10%
NVDANvidia
$221.33+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$75.81+0.01%

Questions About BWAY

What is the current price of BrainsWay?

BrainsWay is trading at $15.37 per share.

What is the 52-week range for BrainsWay?

Over the past 52 weeks, BrainsWay has traded between $5.81 and $17.35.

How much debt does BrainsWay have?

As of the most recent reporting period, BrainsWay reported total debt of $6.71M.

How much cash does BrainsWay have on hand?

BrainsWay reported $58.89M in cash and cash equivalents in its most recent financial results.

What is BrainsWay’s dividend yield?

BrainsWay does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services